Severe Bone Marrow Hypoplasia in a Combined Treatment with Anti PD 1/CTLA-4 in a Patient with Melanoma: A Case Report and Literature Review

Abstract

Immunotherapy with monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and the programmed death-1 receptor and its ligand PD-L1 has become standard of care for an increasing number of indications [1]. In recent years, an increasing number of patients have been exposed to these drugs with a chance of developing toxicities from these treatments [2]. Severe-hematological toxicities have been rarely reported in the literature. We reported a case of a severe bone marrow hypoplasia associated with immunotherapy. The diagnosis was confirmed with bone marrow biopsy after ruling out other pathologies associated with this entity.